maria luz calibo
Sep 10, 2011
Court rules in Allergan's favor on Lumigan patent
WILMINGTON, Del., Sept 9 (Reuters) - Allergan Inc's patent on its Lumigan drug is valid and was infringed by generic versions of the glaucoma treatment from Teva Pharmaceutical Industries Inc and Sandoz Inc, a federal judge ruled. Lumigan has annual global sales of about $650 million, making it one of Allergan's biggest prescription eye medicines. Barr Laboratories Inc, a unit of Teva, and Novartis unit Sandoz filed abbreviated new drug...